GeNeuro, a Geneva-based biopharmaceutical company, has successfully raised €5M through a combination of a private placement and a public offering. This funding will accelerate the company's Phase 2 trial in Post-COVID treatment, marking a significant step forward in addressing the long-term effects of COVID-19.
